Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement. The deal covers Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies, allowing SignalChem Biotech to incorporate these technologies into custom luminescent assay development and protein-fusion services for third-party customers. This collaboration aims to expand SignalChem's specialized CRO capabilities and aligns with Sino Biological's strategy of integrating AI-enabled technologies across its global life science tools and services portfolio.
The significance of this agreement lies in the potential to accelerate research by providing researchers with high-quality discovery candidates more efficiently. Dr. Rob Burgess, Chief Business Officer of Sino Biological, emphasized that incorporating Monod Bio's AI-designed protein technologies into SignalChem's custom assay platform will strengthen their ability to help customers address complex biological questions and advance research programs. The licensed technologies include LuxSit, an AI-designed luciferase engineered for robust luminescent biosensors, and NovoBodies, compact and highly stable binding proteins for high-performance target recognition. Together, these tools offer versatile options for developing customized assays and discovery workflows.
Daniel Silva Manzano, PhD, CEO of Monod Bio, noted that SignalChem Biotech and Sino Biological have the scientific expertise, customer reach, and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of Monod Bio's platform and reinforces the value of their Monod Inside model, which integrates AI-designed proteins into commercial products and services. The agreement is non-exclusive, allowing Monod Bio to license its technologies to other partners as well.
SignalChem Biotech, a wholly-owned subsidiary of Sino Biological, provides specialized reagents and CRO services supporting drug discovery and life science research. Sino Biological is an international life science tools provider with facilities across Asia, North America, and Europe. The company's broad product portfolio means that revenue from this business is not expected to have a material impact on overall financial performance, as stated in the disclaimer.
Monod Bio uses AI-powered de novo protein design to create novel binders, biosensors, and other functional proteins for research and diagnostic applications. Through its Monod Inside model, the company partners with life science firms to integrate its technologies into next-generation products and services. This licensing agreement with SignalChem Biotech is a strategic move that could set a precedent for further adoption of AI-designed proteins in the life science industry, potentially leading to faster and more cost-effective assay development.
The partnership also highlights the growing trend of AI in biotechnology, where machine learning and computational design are being used to engineer proteins with enhanced properties. By leveraging these technologies, SignalChem Biotech can offer more advanced custom assay services, which may attract researchers looking for innovative solutions. As the demand for personalized medicine and targeted therapies grows, the ability to rapidly develop high-quality assays becomes crucial. This collaboration could thus have far-reaching implications for drug discovery and diagnostic development.
For more information about Sino Biological and SignalChem Biotech, visit www.sinobiological.com. For more on Monod Bio, visit monod.bio.
